| A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy. | skin, |
| Effects of interferon-beta on Daudi cells and on small cell lung carcinoma cells which over-express the c-myc oncogene. | lung, |
| Occurrence of human papillomavirus type 16 DNA sequences and c-myc oncogene alterations in uterine-cervix carcinoma. | uterine, |
| Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells. | liver, |
| Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. With special reference to their prognostic significance in carcinoma. | breast, |
| Distribution of the c-myc oncoprotein in normal and neoplastic tissues of the rat colon. | colorectal, |
| Amplification and expression of a cellular oncogene (c-myc) in human gastric adenocarcinoma cells. | gastric, |
| Clinical value of N-myc oncogene amplification in 52 patients with neuroblastoma included in recent therapeutic protocols. | neuroblastoma, |
| MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. | kidney, |
| These data provide evidence for oncogenic properties of Scribble in Myc-driven B-cell lymphomagenesis, reinforcing recent findings that overexpression of a mutant form of Scribble can act as an oncogene in epithelial cells | lymphoma, |
| We defined a novel molecular signature in mammalian HNSCC, suggesting new treatment strategies targeting the GRHL3/GSK3B/c-MYC proto-oncogenic network. | HNSC, |
| Data indicate that diffuse large B-cell lymphoma (DLBCL) patients with proto-oncogene proteins MYC or BCL2 copy number aberration (CNA) constituted a unique group with extremely poor outcome and may require more aggressive treatment regimens. | lymphoma, |
| Data show that proto-oncogene protein c-myc is upregulated by sumoylated heterogeneous nuclear ribonucleoprotein K (hnRNP K) at the translational level in Burkitt_s lymphoma cells. | lymphoma, |
| SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt pathway. | prostate, |
| A search for bcl1, bcl2, and c-myc oncogene rearrangements in chronic lymphocytic leukemia. | leukemia, |
| Data confirmed the validity of the RC cell line as a representative model of proto-oncogene proteins MYC/BCL2 double-hit diffuse large B cell lymphoma. | lymphoma, |
| Data show that overexpression of c-myc proto-oncogene protein could prevent the metabolic shift induced by pituitary tumor-transforming gene (PTTG) knockwown. | pituitary, |
| Data indicate an oncogenic role for an Ikaros protein/MYCBP2 protein/proto-oncogene protein c-MYC axis in adult acute lymphoblastic leukemia (ALL), providing a mechanism of target therapies that activate Ikaros in ALL. | leukemia, |
| our data indicated that there is a regulatory feedback loop between miR-17-5p and c-Myc, in which miR-17-5p could suppress some of the distinguishing features, invasion, and metastasis, of oncogenic c-Myc in HCC cells, and meanwhile, miR-17-5p is upregulated by c-Myc role as a transcription factor, although further studies are still needed | liver, |
| Continued withdrawal from the cell cycle and regulation of cellular genes in mouse erythroleukemia cells blocked in differentiation by the c-myc oncogene. | leukemia, |